文献速递浆细胞疾病造血干细胞移植与细胞治疗

γ-分泌酶抑制增强BCMA CAR-T治疗多发性骨髓瘤疗效

γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.
PubMed 文献 · Blood · 2019-01-01

BCMA是MM中CAR-T治疗的有效靶点,但肿瘤细胞表面BCMA被γ-分泌酶(GS)切割导致抗原密度降低及可溶性BCMA(sBCMA)释放,可能限制疗效。研究发现小分子GS抑制剂(GSIs)可剂量依赖性增加骨髓瘤细胞系和患者样本表面BCMA水平、降低sBCMA并改善CAR-T识别;小鼠模型中GSI治疗增加肿瘤BCMA表达、降低外周血sBCMA并提高BCMA CAR-T抗肿瘤效果。短期GSI给药可显著增加MM患者BCMA+肿瘤细胞比例及表面表达水平,已启动GSI联合BCMA CAR-T的FDA批准临床试验(NCT03502577)。

要点

  • GSIs剂量依赖性增加骨髓瘤细胞表面BCMA并降低sBCMA,改善CAR-T体外识别。
  • 小鼠模型中GSI治疗增强BCMA CAR-T抗肿瘤疗效。
  • 短期GSI给药可增加MM患者BCMA+肿瘤细胞比例及表面表达。

核心结论

  • 抑制γ-分泌酶切割BCMA可提高BCMA靶向CAR-T对多发性骨髓瘤的疗效。

研究设计与样本

  • 体外实验使用骨髓瘤细胞系和患者肿瘤样本;体内使用MM荷瘤NOD/SCID/γc-/-小鼠;并观察MM患者短期GSI给药后的BCMA表达变化。

主要发现

  • GSIs剂量依赖性显著增加骨髓瘤细胞系和患者样本表面BCMA水平,同时降低sBCMA浓度,改善CAR-T体外肿瘤识别。
  • GSI治疗MM荷瘤小鼠增加肿瘤细胞BCMA表达、降低外周血sBCMA,并提高BCMA CAR-T抗肿瘤疗效。
  • 短期GSI给药显著增加MM患者BCMA+肿瘤细胞百分比及体内BCMA表面表达水平。

关键数值与推荐

  • 基于上述数据,已启动FDA批准的临床试验,联合GSI与BCMA CAR-T治疗(NCT03502577)。

临床怎么用

  • GSI联合BCMA CAR-T可能通过增加肿瘤表面BCMA密度和减少sBCMA抑制来增强疗效,目前处于临床试验阶段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

B-cell maturation antigen (BCMA) is a validated target for chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM). Despite promising objective response rates, most patients relapse, and low levels of BCMA on a subset of tumor cells has been suggested as a probable escape mechanism. BCMA is actively cleaved from the tumor cell surface by the ubiquitous multisubunit γ-secretase (GS) complex, which reduces ligand density on tumor cells for CAR T-cell recognition and releases a soluble BCMA (sBCMA) fragment capable of inhibiting CAR T-cell function. Sufficient sBCMA can accumulate in the bone marrow of MM patients to inhibit CAR T-cell recognition of tumor cells, and potentially limit efficacy of BCMA-directed adoptive T-cell therapy. We investigated whether blocking BCMA cleavage by small-molecule GS inhibitors (GSIs) could augment BCMA-targeted CAR T-cell therapy. We found that exposure of myeloma cell lines and patient tumor samples to GSIs markedly increased surface BCMA levels in a dose-dependent fashion, concurrently decreased sBCMA concentrations, and improved tumor recognition by CAR T cells in vitro. GSI treatment of MM tumor-bearing NOD/SCID/γc-/- mice increased BCMA expression on tumor cells, decreased sBCMA in peripheral blood, and improved antitumor efficacy of BCMA-targeted CAR T-cell therapy. Importantly, short-term GSI administration to MM patients markedly increases the percentage of BCMA+ tumor cells, and the levels of BCMA surface expression in vivo. Based on these data, a US Food and Drug Administration (FDA)-approved clinical trial has been initiated, combining GSI with concurrent BCMA CAR T-cell therapy. This trial was registered at www.clinicaltrials.gov as #NCT03502577.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Pont MJ, Hill T, Cole GO, et al. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019. PMID: 31558469. doi:10.1182/blood.2019000050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。